Kellogg Company (K) Reaches $64.57 After 6.00% Up Move; Calithera Biosciences (CALA) Covered By 4 Bulls

November 14, 2017 - By Winifred Garcia

The stock of Kellogg Company (NYSE:K) is a huge mover today! About 673,125 shares traded. Kellogg Company (NYSE:K) has declined 5.60% since November 14, 2016 and is downtrending. It has underperformed by 22.30% the S&P500.The move comes after 7 months positive chart setup for the $22.29B company. It was reported on Nov, 14 by Barchart.com. We have $68.44 PT which if reached, will make NYSE:K worth $1.34B more.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Calithera Biosciences had 9 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Calithera Biosciences Inc (NASDAQ:CALA) has “Buy” rating given on Friday, July 24 by Citigroup. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. H.C. Wainwright initiated the shares of CALA in report on Thursday, January 5 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $14 target in Tuesday, March 28 report. On Tuesday, January 24 the stock rating was upgraded by Citigroup to “Neutral”. As per Monday, June 12, the company rating was maintained by H.C. Wainwright. The rating was initiated by Citigroup on Tuesday, October 25 with “Sell”. See Calithera Biosciences Inc (NASDAQ:CALA) latest ratings:

05/10/2017 Broker: William Blair Rating: Outperform Initiates Coverage On
12/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $19.0000 Maintain

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $388.47 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Investors sentiment decreased to 3.25 in Q2 2017. Its down 2.64, from 5.89 in 2017Q1. It turned negative, as 11 investors sold Calithera Biosciences Inc shares while 9 reduced holdings. 34 funds opened positions while 31 raised stakes. 49.95 million shares or 37.35% more from 36.36 million shares in 2017Q1 were reported. Century reported 0% stake. Viking Investors L P has 0.24% invested in Calithera Biosciences Inc (NASDAQ:CALA). Cubist Systematic Strategies Ltd Company holds 14,972 shares or 0.01% of its portfolio. Morgan Stanley has 118,481 shares. Pdt Partners Lc, a New York-based fund reported 18,690 shares. Pnc Financial Ser Inc holds 1,000 shares. Lord Abbett Ltd has invested 0.02% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). 32,229 were reported by Credit Suisse Ag. Gam Hldg Ag has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 13,900 shares. Interest Gru reported 19,000 shares stake. Northern accumulated 0% or 337,640 shares. 2.06M were accumulated by Blackrock. Financial Bank Of Ny Mellon Corp accumulated 108,102 shares. Citigroup invested in 42,405 shares or 0% of the stock. D E Shaw reported 41,433 shares.

About 397,145 shares traded. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since November 14, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.

Since June 1, 2017, it had 0 insider buys, and 2 sales for $2.20 million activity. KELLOGG W K FOUNDATION TRUST sold $1.85M worth of Kellogg Company (NYSE:K) on Wednesday, June 14. $352,140 worth of Kellogg Company (NYSE:K) was sold by DILLON JOHN T on Thursday, June 1.

Analysts await Kellogg Company (NYSE:K) to report earnings on February, 8. They expect $0.96 EPS, up 4.35% or $0.04 from last year’s $0.92 per share. K’s profit will be $331.40M for 16.82 P/E if the $0.96 EPS becomes a reality. After $1.05 actual EPS reported by Kellogg Company for the previous quarter, Wall Street now forecasts -8.57% negative EPS growth.

Kellogg Company is a manufacturer and marketer of ready-to-eat cereal and convenience foods. The company has market cap of $22.29 billion. The Company’s principal products are ready-to-eat cereals and convenience foods, such as cookies, crackers, savory snacks, toaster pastries, cereal bars, fruit-flavored snacks, frozen waffles and veggie foods. It has a 28.78 P/E ratio. The Company’s divisions include U.S.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com